1. Home
  2. CRAI vs DVAX Comparison

CRAI vs DVAX Comparison

Compare CRAI & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRAI
  • DVAX
  • Stock Information
  • Founded
  • CRAI 1965
  • DVAX 1996
  • Country
  • CRAI United States
  • DVAX United States
  • Employees
  • CRAI N/A
  • DVAX N/A
  • Industry
  • CRAI Other Consumer Services
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRAI Consumer Discretionary
  • DVAX Health Care
  • Exchange
  • CRAI Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • CRAI 1.3B
  • DVAX 1.3B
  • IPO Year
  • CRAI 1998
  • DVAX 2004
  • Fundamental
  • Price
  • CRAI $198.17
  • DVAX $9.41
  • Analyst Decision
  • CRAI Buy
  • DVAX Buy
  • Analyst Count
  • CRAI 1
  • DVAX 4
  • Target Price
  • CRAI $228.00
  • DVAX $26.50
  • AVG Volume (30 Days)
  • CRAI 78.9K
  • DVAX 1.9M
  • Earning Date
  • CRAI 10-30-2025
  • DVAX 11-06-2025
  • Dividend Yield
  • CRAI 0.99%
  • DVAX N/A
  • EPS Growth
  • CRAI 44.21
  • DVAX N/A
  • EPS
  • CRAI 8.27
  • DVAX N/A
  • Revenue
  • CRAI $712,913,000.00
  • DVAX $316,268,000.00
  • Revenue This Year
  • CRAI $9.01
  • DVAX $23.23
  • Revenue Next Year
  • CRAI $4.26
  • DVAX $16.57
  • P/E Ratio
  • CRAI $23.98
  • DVAX N/A
  • Revenue Growth
  • CRAI 9.28
  • DVAX 26.66
  • 52 Week Low
  • CRAI $152.57
  • DVAX $9.22
  • 52 Week High
  • CRAI $214.01
  • DVAX $14.63
  • Technical
  • Relative Strength Index (RSI)
  • CRAI 58.22
  • DVAX 33.66
  • Support Level
  • CRAI $191.56
  • DVAX $9.51
  • Resistance Level
  • CRAI $198.89
  • DVAX $9.94
  • Average True Range (ATR)
  • CRAI 4.44
  • DVAX 0.29
  • MACD
  • CRAI -0.01
  • DVAX -0.07
  • Stochastic Oscillator
  • CRAI 73.46
  • DVAX 0.85

About CRAI CRA International Inc.

CRA International Inc is a U.S.-based advisory firm that provides economic, financial, and management consultancy services. The company advises clients on economic and financial issues relating to litigation and regulatory proceedings and helps businesses set important business strategies and solve performance-related issues. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. CRA International generates majority of its revenue from the United States, while it also has its presence in United Kingdom and Other Countries.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: